FOXO4-DRI Senolytic Peptide

FOXO4-DRI is an experimental peptide designed to break a link between two proteins that keep 'worn-out' cells alive. Clearing those cells is a focus of aging research.

It's studied in longevity research — how the body removes senescent (old, damaging) cells and restores tissue balance.

Mouse studies showed clearance of old cells and some reversal of frailty. No human data exists; benefits are unproven.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

FOXO4-DRI is an experimental research chemical. It is not approved by the FDA for any human use.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

Potent senolytic; monitor p53-pathway disruption in non-target cell cultures.

• Baar MP et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis. Cell. 2017.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.